The Stock Movers podcast from Bloomberg
04:33 Share

Bloomberg Audio Studios. Podcasts. Radio. News. The Stock Movers Podcast. Your roundup of companies making moves in the stock market. Harnessing the power of Bloomberg data.

Right now, we need to take a look at some stocks on the move today. We're joined by Bloomberg's Lisa Mateo. Lisa? I want to start with Tesla, leading the MAG7 stocks lower. Shares have been down more than 5% this morning. Its first quarter delivery is expected to release Wednesday, but it really snapped this nine-week losing streak last week.

And you had Elon Musk. He was at a town hall event in Wisconsin over the weekend. And he said that his doge roll, it's costing him a lot. His words, Tesla shares rose to a record high in the month after Trump was elected. But here's the thing. They've dropped 45% since their December 17th week. And then you go to Musk's own personal wealth itself, declined by more than a hundred billion this year. I mean, basically Paul, hold is a sell, right? On the ANR screen,

On the terminal, I got 33 buys and 27 holds or sells.

So it's a huge debate. Which to me just raises the question, why don't we have 60, six zero analysts covering one stock? Granted, it's Tesla, but do I need 60 opinions? I mean, there's some people at BNP Paribas, Underperform, HSBC, Reduce, Hedgeye Risk. Good morning to everybody over at Hedgeye. Wells Fargo. No, but Elon's right. I mean, he admitted it over the weekend. You know, his Doge activities. Adam Jonas or Morgan Stanley, he always gets love.

He's got a price target. Lisa could make money at this up 410. The next mover, please. These are stick with me here because these are investors exposed to the AI trades. So, for example, Palantir shares have been down as much as 7 percent before the bell. One of the reasons that I found the Pentagon actually canceled a 280 million dollar over budget H.R. project.

involving Oracle. Now, the reason why that matters to Palantir is because Palantir relies on these government contracts, including those with the Department of Defense. And they, Department of Defense, recently announced an additional $580 million in budget reductions. And then you, of course, also had Goldman Sachs analysts maintain a neutral rating, but they talk

about concerns about the potential future competition from companies developing in-house AI. So then we hit Palantir and we go to NVIDIA. They have been down about 18% on the year coming into Monday, coming into today. Disappointing IPO from the companies that it's backing. CoreWeave, remember we talked about that last week? Yeah, with that it came out. It began trading Friday. Shares fell below its offering price of $40. So that's why those shares. It's funny though that they got that print, they got that

stock to close at 40. At 40, yeah. You know that the desk was working hard. The underwriters to get close. I don't want this thing to close down. Make sure you find something to push the stock up to 40 at the close, and they did. So we'll see how it trades today. I would say, yeah. And finally, we've been talking a lot about gold, right? That's hitting a record. Newmont Corporation, they're the leading global gold and copper company. They're known for its extensive portfolio mining assets.

Since we've been talking about gold, we're reaching that fresh record high, rising above $3,100. So you see this a lot. I mean, investors making these defensive plays over policy and starting to op out the U.S. tariff. So they're going to this safe haven. That's why you have Newmont Corporation. Their shares have been up probably about 1% this morning. Yeah, 12 months up, 37% up. How many companies can say that? Yeah, exactly. And this year, after 23 and 24, great performances. Good morning, Denver. 22,000 people, Newmont.

Numat Mining.

Yep. I mean, I don't know. What else? Do you have a fourth one, Lisa? Is there an audible here? Here's an audible. Yeah, Moderna. Moderna has been down, gosh, about 13% in trading before the bell opens. The reason why, here's something interesting. The resignation of Peter Marks, he's a top regulator at the U.S. Food and Drug Administration. He has been overseeing approvals of vaccine and other biological drugs. So he resigned. And now you have those Moderna shares plunging.

The Stock Movers Podcast from Bloomberg Radio. Check back with us throughout the day for the latest roundup of companies making news on Wall Street. And for the latest market-moving headlines, listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com, and on Apple CarPlay and Android Auto with the Bloomberg Business app.